The Collaborative Research Board (CRB) represents individual scientists who have agreed to conduct research on behalf of Immugen.  These are outstanding senior scientists with a proven track record in clinical research.  The areas of research we have identified are varied, but for the most part, should lead to  proof-of-concept in the areas of immune response to infectious disease, in particular HIV and influenza.

As certain funding thresholds are achieved, other research projects will be addressed which will lead to the clinical use of the drug for the treatment or prevention of disease.  Among these research areas are:

• Atherosclerosis prevention
• Inflammatory bowel diseases
• Autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis
• Prevention of allograft rejection - Host vs. graft and graft vs. host
• Cancer